Citi has initiated coverage of EyePoint Pharmaceuticals (NASDAQ:EYPT) with a buy rating, stating it sees the company's drug ...
BlackRock — which for years has courted controversy with its focus on so-called ESG, or Environmental Social Governance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback